The proposed research will evaluate the ability of a mobile, rapid induction procedure to
engage individuals in ongoing medication assisted treatment. A total of 250 untreated
individuals meeting criteria for opioid use disorder and at high risk of opioid overdose will
be enrolled in the study. Recruitment will take place in two targeted neighborhoods of
Philadelphia (Kensington and South Philadelphia) with a high prevalence of fatal and
non-fatal opioid overdose. A total of 250 participants will be engaged in the research.
Following informed consent and determination of eligibility, 125 individuals will be enrolled
as they engage with the mobile, rapid induction team and 125 individuals will be enrolled as
they seek treatment from the CRC Episcopal Hospital (serving Kensington area) or BAC/CRC Hall
Mercer Community Mental Health (serving South Philadelphia). The intervention group will
receive four weeks of treatment with buprenorphine /naloxone and support for treatment
engagement provided by a case manager and a peer recovery specialist. All participants will
be assessed at baseline and then 1- and 6-month following enrollment. The primary endpoint
for the study is continued enrollment in medication-assisted treatment at 6-month
post-enrollment.
The proposed research will evaluate the ability of a mobile, rapid induction procedure to
engage individuals in ongoing medication assisted treatment.
The specific aims are:
- Aim 1: To evaluate the impact of the mobile, transitional MAT intervention on its
ability to engage participants in targeted, existing MAT treatment slots at 1- and
6-month post-enrollment.
- Aim 2: To evaluate the impact of the mobile intervention on subsequent drug use and
overdoses at 6-month post-enrollment.
- Aim 3: To assess the acceptability and costs of the intervention. The program and
patient costs of delivering and participating in the intervention will be documented.
Phase:
Phase 4
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Philadelphia Department of Public Health Prevention Point Philadelphia Public Health Management Corporation
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone